文献速递类风湿关节炎

巴瑞替尼治疗类风湿关节炎中JAK1/JAK2抑制相关的血液学参数变化

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.
PubMed 文献 · RMD Open · 2020-01-01

汇总8项随机临床试验和1项长期扩展研究,评估巴瑞替尼治疗类风湿关节炎患者血液学参数变化。中性粒细胞轻度下降后稳定于正常范围,淋巴细胞和血小板短暂升高后回归基线,血红蛋白变化小,血液学异常导致停药少见。

要点

  • 中性粒细胞计数1个月内平均下降-1.36×10^9/L,后稳定于正常参考范围内至第128周。
  • 淋巴细胞计数1个月内平均升高+0.30×10^9/L,第12-24周降至基线;血小板第2周平均升高+51×10^9/L后向基线回落。
  • 因中性粒细胞计数、淋巴细胞计数、血小板计数和血红蛋白水平相关实验室异常永久停药的患者分别占全部巴瑞替尼治疗患者的8例(0.2%)、6例(0.2%)、8例(0.2%)和16例(0.5%)。

核心结论

  • 巴瑞替尼治疗类风湿关节炎患者中观察到中性粒细胞中度下降,但中性粒细胞减少患者严重感染不常见。
  • 淋巴细胞和血小板出现短暂升高,随时间回归基线,血红蛋白浓度变化一般较小,血液学异常很少导致停药。

研究设计与样本

  • 汇总8项随机临床试验(4项3期、3项2期、1项1b期)和1项长期扩展研究的数据。
  • 血液学参数变化评估长达128周(N=2387),巴瑞替尼总体安全性评估长达6年(N=3492)。

主要发现

  • 中性粒细胞绝对计数1个月内平均下降-1.36×10^9/L,随后稳定于正常参考范围内至第128周。
  • 24周安慰剂对照期间,中性粒细胞减少患者严重感染发生率未升高。
  • 淋巴细胞计数1个月内平均升高+0.30×10^9/L,第12-24周降至基线。
  • 血小板计数第2周平均升高+51×10^9/L,后向基线下降。
  • 血红蛋白浓度总体平均下降-0.12 mmol/L后回归基线,但基线高敏C反应蛋白最高四分位组中基线血红蛋白降低者随时间升高。

关键数值与推荐

  • 全部巴瑞替尼治疗患者(N=3492,总暴露7993人年)中,因中性粒细胞计数相关实验室异常永久停药8例(0.2%)。
  • 因淋巴细胞计数相关实验室异常永久停药6例(0.2%),因血小板计数相关实验室异常永久停药8例(0.2%),因血红蛋白水平相关实验室异常永久停药16例(0.5%)。

临床怎么用

  • 巴瑞替尼治疗期间应监测中性粒细胞计数,但中性粒细胞减少患者严重感染不常见。
  • 淋巴细胞和血小板短暂升高通常无需特殊处理,可随时间回归基线。
  • 血红蛋白变化一般较小,血液学异常很少需要永久停药。

局限性

  • 数据来自汇总的临床试验和长期扩展研究,非真实世界人群。
  • 血液学参数变化评估最长128周,长期安全性评估虽达6年但血液学参数未持续至6年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing. METHODS: Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extension. Changes in haematological parameters were evaluated up to 128 weeks (N=2387); overall safety of baricitinib was assessed up to 6 years (N=3492). RESULTS: Mean absolute neutrophil counts decreased (-1.36×109/L) within 1 month, followed by stabilisation within the normal reference range through week 128. The incidence of serious infections was not elevated in patients with neutropenia during the 24-week placebo-controlled period. Mean lymphocyte counts increased (+0.30×109/L) within 1 month, then decreased to baseline (weeks 12-24). Mean platelet counts increased at week 2 (+51×109/L), then decreased towards baseline. Overall, mean haemoglobin concentrations decreased (-0.12 mmol/L), then returned to baseline; however, reduced baseline haemoglobin concentrations observed in the highest baseline high-sensitivity C reactive protein quartile increased over time. Permanent drug discontinuation occurred due to laboratory abnormalities related to neutrophil count in 8 (0.2%), lymphocyte counts in 6 (0.2%), platelet counts in 8 (0.2%), and haemoglobin levels in 16 (0.5%) of all baricitinib-treated patients (N=3492 with 7993 total person-years of exposure). CONCLUSIONS: Moderate decreases in neutrophils were seen during baricitinib treatment; however, serious infection was uncommon in patients with neutropenia. Transient increases were observed in lymphocytes and platelets, which returned to baseline over time. Changes in haemoglobin concentration were generally small. Haematological abnormalities seldom led to drug discontinuation.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kay J, Harigai M, Rancourt J, et al. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020. PMID: 33028675. doi:10.1136/rmdopen-2020-001370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。